Baird Maintains Outperform on Coherus BioSciences, Lowers Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Colleen Kusy maintains an Outperform rating on Coherus BioSciences (NASDAQ:CHRS) but lowers the price target from $9 to $8.
July 01, 2024 | 11:20 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Baird analyst Colleen Kusy maintains an Outperform rating on Coherus BioSciences but lowers the price target from $9 to $8.
The Outperform rating suggests continued confidence in the company's performance, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100